Scholarlink

<p>Cardiac resynchronization therapy (CRT) has gained a&#xa0;new partner in the treatment of systolic heart failure with the possibility of lead system stimulation. In parallel, leadless systems for right ventricular stimulation are being used, particularly in cases of venous access problems, infections, or other complications associated with leads. Endocardial, leadless left ventricular stimulation has been in clinical use for over 10&#xa0;years now and is continuously being developed. It offers the alternative of stimulating the left ventricle endocardially and leadlessly via a&#xa0;co-implant, either posterolateral–basal or at the left (Tawara) branch of the left ventricular endocardium. This article presents the development, previous challenges, and new approaches to the implantation of the WiSE-CRT system (wireless stimulation endocardially). In addition, the clinical data situation and current approvals will be discussed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Endokardiale linksventrikuläre Stimulation im Jahr 2025

  • 期刊论文

  • 发表日期：

    2025年10月27日

查看全文
  • Martin Seifert,
  • Christian Georgi,
  • Paulina Jankowska,
  • Marwin Bannehr,
  • Christian Butter

摘要

Cardiac resynchronization therapy (CRT) has gained a new partner in the treatment of systolic heart failure with the possibility of lead system stimulation. In parallel, leadless systems for right ventricular stimulation are being used, particularly in cases of venous access problems, infections, or other complications associated with leads. Endocardial, leadless left ventricular stimulation has been in clinical use for over 10 years now and is continuously being developed. It offers the alternative of stimulating the left ventricle endocardially and leadlessly via a co-implant, either posterolateral–basal or at the left (Tawara) branch of the left ventricular endocardium. This article presents the development, previous challenges, and new approaches to the implantation of the WiSE-CRT system (wireless stimulation endocardially). In addition, the clinical data situation and current approvals will be discussed.